ArticleCancer medicine2023
Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study.
Wei-Jun Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
34 papers cite it
this paperpooled itcites it